Atalanta Therapeutics secures $97m in Series B round to advance RNAi therapies
Atalanta Therapeutics has secured oversubscribed $97m in Series B financing to propel the Phase I trials of its RNA interference (RNAi) treatments targeting KCNT1-related epilepsy as well as Huntington’s disease.